Tufts Study Uncovers the Economic Advantage of Single-Source Drug Development and Manufacturing

Small and emerging biotech companies need three things to get started in early development: a molecule, funding and speed. The Tufts Center for the Study of Drug Development (CSDD) recently compared cycle times and development economics between multi- and single-source CDMO models – finding that if you plan for drug substance and drug product early in development, you can reap the benefits of approximately $45 million in net gains from time savings and increased revenue.

Download the article, “Tufts Study Uncovers the Economic Advantage of Single-Source Drug Development and Manufacturing,” to explore the results of the study.

Max Character Limit 45

Max Character Limit 45

Max Character Limit 460 - error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto.